Gabapentin + Placebo
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Dyspepsia
Conditions
Functional Dyspepsia
Trial Timeline
Mar 1, 2010 → Aug 28, 2012
NCT ID
NCT01052896About Gabapentin + Placebo
Gabapentin + Placebo is a phase 3 stage product being developed by Pfizer for Functional Dyspepsia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01052896. Target conditions include Functional Dyspepsia.
What happened to similar drugs?
0 of 5 similar drugs in Functional Dyspepsia were approved
Approved (0) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01052896 | Phase 3 | Withdrawn |
| NCT00163046 | Phase 3 | Completed |
| NCT00666575 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Dyspepsia